Because HAT1-KO melanoma cells became BRAFi resistant during a clonogenic long-term survival assay, we next tested whether HAT1 expression was downregulated in clinical samples taken from patients who experienced disease progression following treatment with BRAFi or BRAFi+MEKi. This evidence concerns the gene HAT1 and melanoma.